Programma finale completo - SIF - Università degli Studi di Torino

Farmacologia clinica e sperimentazione clinica dei farmaci
Poster 225 – 240
225. Quality of life of pediatric patients with attention deficit hyperactivity disorder and
oppositive defiant disorder: an italian double-blind placebo-controlled study with
atomoxetine
Dell’Agnello Grazia 2 , Curatolo P. 1 , Mancini F. 2
1 Neuropsychiatria Infantile Clinica Sant’Alessandro, Rome, Italy; 2 Eli Lilly Italia
226. Evening and early morning administration of atomozetine in ADHD children: a
comparison
Dell’Agnello Grazia 4 , Kelsey D. 1 , Sutton V. 1 , Lewis D. 2 , Schuh K. 1 ; Sumner C. 1 , Quintana H. 3 ,
Frediani S. 4 , Rossi A. 4
1 Lilly Research Laboratories,Indianapolis,IN;
2 Monarch Medical Research,Norfolk,VA;
3 Louisiana State University Health Science Center,New Orleans,LA; 4 Eli Lilly Italia
227. Safety and tolerability of duloxetine in the treatment of major depressive disorder:
analysis of pooled data from eight placebo-controlled clinical trials
Mancini Michele, Barraco A., Rossi A.
Eli Lilly Italia S.p.A.
228. The new antidepressant duloxetine: cardiovascular effects
Mancini Michele, Barraco A., Rossi A.
Eli Lilly Italia S.p.A.
229. The management of bipolar mania: a national survey of baseline data from the
emblem study
Mancini Michele 2 , Bellantuono C. 1 , Rossi A. 2 , Barraco A. 2 , Goetz I. 3 , for the Italian EMBLEM
study group
1 Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology,
University of Verona, Italy; 2 Eli Lilly Italia S.p.A. for the Italian EMBLEM study group; 3 Eli Lilly
and Company, Windlesham, UK
141
230. European mania in bipolar longitudinal evaluation of medication (emblem) study:
results of the acute 12-week phase in Italy by regional location (north, centre and
south)
Mancini Michele 1 , Rossi A. 1 , Barraco A.1, Goetz I. 2 , for the Italian EMBLEM study group
1 Eli Lilly Italia S.p.A.; 2 Eli Lilly and Company, Windlesham, UK
231. Effectiveness of antipsychotic treatment in outpatients with schizophrenia: 36-
month results from the schizophrenia outpatients health outcomes (SOHO) study
Scatigna Marco (3) , Novick Diego (1) , Haro Josè M. (2) , Brown James (1) , Suarez Diego (2) , Rossi
Andrea (3) , Frediani Sonia (3) , Ratcliffe Mark C. (1) , and the SOHO Study Group (4)
(1) Eli Lilly and Company, Windlesham, UK (2) Unità ricerca e sviluppo, San Joan de Deu-SSM,
Sant Boi, Barcellona, Spagna (3) Eli illy Italia S.p.A. (4) Alonso J (SP), Gasquet I (FR), Haro JM
(SP) Jones PB (UK), Knapp M (UK), Lepine JP (FR), Naber D (DE), Slooff CJ (NL)
232. Tolerability of outpatient antipsychotic treatment: 36-month results from the
european schizophrenia outpatients health outcomes (soho) study
Scatigna Marco (5) , Novick D. (1) , Haro Josè M. (2) , Suarez D. (2) , Bushe C. (3) , Lepine A. (4) , Rossi
A. (5) , Frediani S. (5) , the SOHO Study Group (6)
(1) Eli Lilly and Company, Windlesham, UK (2) Unità ricerca e sviluppo, San Joan de Deu-SSM,
Sant Boi, Barcellona, Spagna (3) Eli Lilly and Company, Basingstoke, UK; (4) Hôpital Fernand
Widal Parigi Cedex 10 (5) Eli Lilly Italia S.p.A. (6) Alonso J (SP), Gasquet I (FR), Haro JM (SP)
Jones PB (UK), Knapp M (UK), Lepine JP (FR), Naber D (DE), Slooff CJ (NL)
pag_dx.indd 1 30/05/2007 5.57.26